A decision by the CDC to send the limited available testing kits roughly evenly throughout the U.S. seems to have resulted in a massive disconnect between testing availability and actual needs.
As the pandemic has worn on, testing supply deployment processes by the IRR have become more mature, and many of these hurdles have been overcome.
So, are we all just stuck getting stabbed up the nose? Not necessarily – innovation is at its peak right now, with many different types of tests being developed.
On February 29, the FDA issued an updated policy which allowed labs outside of the CDC to make and distribute PCR tests; and since March, these PCR tests have been made and distributed at a wide scale.
With lives on the line, our apparent lack of testing availability will certainly continue to persist without urgent, rigorous detection and testing initiatives to control the coronavirus outbreak.